Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-03-03
DOI
10.1038/s41571-021-00479-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide
- (2021) Max Jan et al. Science Translational Medicine
- Clinical Activity of CC-90009, a Cereblon E3 Ligase Modulator and First-in-Class GSPT1 Degrader, As a Single Agent in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding Study
- (2020) Geoffrey L. Uy et al. BLOOD
- Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
- (2020) George M. Burslem et al. CELL
- PIKES Analysis Reveals Response to Degraders and Key Regulatory Mechanisms of the CRL4 Network
- (2020) Kurt M. Reichermeier et al. MOLECULAR CELL
- Harnessing the Power of Proteolysis for Targeted Protein Inactivation
- (2020) Rati Verma et al. MOLECULAR CELL
- Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide
- (2020) Shumpei Tateno et al. Scientific Reports
- The Emerging Landscape of Immune Cell Therapies
- (2020) Evan W. Weber et al. CELL
- Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome
- (2020) Sergio Martinez-Høyer et al. NATURE CELL BIOLOGY
- Unifying principles of bifunctional, proximity-inducing small molecules
- (2020) Christopher J. Gerry et al. Nature Chemical Biology
- A Chemical Switch System to Modulate Chimeric Antigen Receptor T Cell Activity through Proteolysis-Targeting Chimaera Technology
- (2020) So Myoung Lee et al. ACS Synthetic Biology
- Multiple Cereblon genetic changes associate with acquired resistance to Lenalidomide or Pomalidomide in Multiple Myeloma
- (2020) Sarah Gooding et al. BLOOD
- Lysosome-targeting chimaeras for degradation of extracellular proteins
- (2020) Steven M. Banik et al. NATURE
- The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K
- (2020) Mikołaj Słabicki et al. NATURE
- Rational discovery of molecular glue degraders via scalable chemical profiling
- (2020) Cristina Mayor-Ruiz et al. Nature Chemical Biology
- Mechanisms of lenalidomide sensitivity and resistance
- (2020) Sergio Martinez-Høyer et al. EXPERIMENTAL HEMATOLOGY
- Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation
- (2020) Lu Lv et al. eLife
- Small-molecule-induced polymerization triggers degradation of BCL6
- (2020) Mikołaj Słabicki et al. NATURE
- Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia
- (2019) Charles Craddock et al. JOURNAL OF CLINICAL ONCOLOGY
- The extended 4-year follow-up results of the ELOQUENT-2 trial
- (2019) Maria Gavriatopoulou et al. Oncotarget
- Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction
- (2019) Kyle R. Simonetta et al. Nature Communications
- Peptidic degron for IMiD-induced degradation of heterologous proteins
- (2019) Vidyasagar Koduri et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
- (2019) John P. Leonard et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic Multicentric Castleman disease
- (2019) Lu Zhang et al. BLOOD
- Patterns of substrate affinity, competition and degradation kinetics underlie biological activity of thalidomide analogs
- (2019) Adam S. Sperling et al. BLOOD
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
- (2019) Thierry Facon et al. NEW ENGLAND JOURNAL OF MEDICINE
- ROBUST: First report of phase III randomized study of lenalidomide/R-CHOP (R2 -CHOP) vs placebo/R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma
- (2019) U. Vitolo et al. HEMATOLOGICAL ONCOLOGY
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
- (2019) Philippe Moreau et al. LANCET
- Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
- (2019) Paul G Richardson et al. LANCET ONCOLOGY
- Development of targeted protein degradation therapeutics
- (2019) Philip P. Chamberlain et al. Nature Chemical Biology
- Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial
- (2019) E. Antonio Chiocca et al. Science Translational Medicine
- Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study
- (2019) Franck Morschhauser et al. Lancet Haematology
- CC-92480 Is a Novel Cereblon E3 Ligase Modulator with Enhanced Tumoricidal and Immunomodulatory Activity Against Sensitive and Resistant Multiple Myeloma Cells
- (2019) Antonia Lopez-Girona et al. BLOOD
- Pomalidomide plus low‐dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure
- (2019) David S. Siegel et al. BRITISH JOURNAL OF HAEMATOLOGY
- Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN
- (2019) Chad C. Bjorklund et al. LEUKEMIA
- Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15
- (2019) Tyler B. Faust et al. Nature Chemical Biology
- Targeted protein degradation: expanding the toolbox
- (2019) Matthieu Schapira et al. NATURE REVIEWS DRUG DISCOVERY
- Structural Basis and Kinetic Pathway of RBM39 Recruitment to DCAF15 by a Sulfonamide Molecular Glue E7820
- (2019) Xinlin Du et al. STRUCTURE
- Aryl Sulfonamides Degrade RBM39 and RBM23 by Recruitment to CRL4-DCAF15
- (2019) Tabitha C. Ting et al. Cell Reports
- Heterobifunctional Molecules Induce Dephosphorylation of Kinases–A Proof of Concept Study
- (2019) Sayumi Yamazoe et al. JOURNAL OF MEDICINAL CHEMISTRY
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
- (2019) Michel Attal et al. LANCET
- Discovery of a first-in-class EZH2 selective degrader
- (2019) Anqi Ma et al. Nature Chemical Biology
- Targeting the C481S Ibrutinib-Resistance Mutation in Bruton’s Tyrosine Kinase Using PROTAC-Mediated Degradation
- (2018) Alexandru D. Buhimschi et al. BIOCHEMISTRY
- Targeted protein degradation and the enzymology of degraders
- (2018) Stewart L Fisher et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients
- (2018) Laurens E. Franssen et al. HAEMATOLOGICA
- Dominant-negative IKZF1 mutations cause a T, B, and myeloid cell combined immunodeficiency
- (2018) David Boutboul et al. JOURNAL OF CLINICAL INVESTIGATION
- A decade of progress in myelodysplastic syndrome with chromosome 5q deletion
- (2018) Alan List et al. LEUKEMIA
- The dTAG system for immediate and target-specific protein degradation
- (2018) Behnam Nabet et al. Nature Chemical Biology
- Plasticity in binding confers selectivity in ligand-induced protein degradation
- (2018) Radosław P. Nowak et al. Nature Chemical Biology
- Chemically induced proximity in biology and medicine
- (2018) Benjamin Z. Stanton et al. SCIENCE
- Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients
- (2018) Laurens E. Franssen et al. HAEMATOLOGICA
- Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4CRBN activity
- (2018) Quinlan L. Sievers et al. BLOOD
- Biology and management of primary effusion lymphoma
- (2018) Kazuyuki Shimada et al. BLOOD
- SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate
- (2018) Mary E. Matyskiela et al. Nature Chemical Biology
- Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
- (2018) Franck Morschhauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome
- (2018) Katherine A Donovan et al. eLife
- Bruton's Tyrosine Kinase degradation as a therapeutic strategy for cancer
- (2018) Dennis Dobrovolsky et al. BLOOD
- Clinical potential of mass spectrometry-based proteogenomics
- (2018) Bing Zhang et al. Nature Reviews Clinical Oncology
- Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
- (2018) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN
- (2018) Quinlan L. Sievers et al. SCIENCE
- Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide
- (2017) Laurence Lodé et al. HAEMATOLOGICA
- Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
- (2017) Philip L. McCarthy et al. JOURNAL OF CLINICAL ONCOLOGY
- A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos
- (2017) Mary E. Matyskiela et al. JOURNAL OF MEDICINAL CHEMISTRY
- Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial
- (2017) H Goldschmidt et al. LEUKEMIA
- Selective degradation of splicing factor CAPERα by anticancer sulfonamides
- (2017) Taisuke Uehara et al. Nature Chemical Biology
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
- (2017) Sattva S. Neelapu et al. Nature Reviews Clinical Oncology
- Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15
- (2017) Ting Han et al. SCIENCE
- pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase
- (2017) Jian An et al. Nature Communications
- Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6
- (2017) Nina Kerres et al. Cell Reports
- Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide
- (2017) Laurence Lodé et al. HAEMATOLOGICA
- Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Asher A Chanan-Khan et al. Lancet Haematology
- Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial
- (2017) Andrés J M Ferreri et al. Lancet Haematology
- Second primary malignancies in multiple myeloma: an overview and IMWG consensus
- (2016) P. Musto et al. ANNALS OF ONCOLOGY
- Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes
- (2016) K. M. Kortum et al. BLOOD
- Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma
- (2016) Emily Rychak et al. BRITISH JOURNAL OF HAEMATOLOGY
- Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations
- (2016) Christian Scharenberg et al. HAEMATOLOGICA
- Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study
- (2016) Mark N. Polizzotto et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002
- (2016) Takashi Ishida et al. JOURNAL OF CLINICAL ONCOLOGY
- High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide
- (2016) Maryam Pourabdollah et al. Journal of Hematology & Oncology
- Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial
- (2016) Marek Trněný et al. LANCET ONCOLOGY
- IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM)
- (2016) J Krönke et al. LEUKEMIA
- Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis
- (2016) Dai Chihara et al. LEUKEMIA RESEARCH
- Glutamine Triggers Acetylation-Dependent Degradation of Glutamine Synthetase via the Thalidomide Receptor Cereblon
- (2016) Thang Van Nguyen et al. MOLECULAR CELL
- A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase
- (2016) Mary E. Matyskiela et al. NATURE
- Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase
- (2016) Georg Petzold et al. NATURE
- A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes
- (2016) Jing Fang et al. NATURE MEDICINE
- Immunomodulatory drugs disrupt the cereblon–CD147–MCT1 axis to exert antitumor activity and teratogenicity
- (2016) Ruth Eichner et al. NATURE MEDICINE
- Induced protein degradation: an emerging drug discovery paradigm
- (2016) Ashton C. Lai et al. NATURE REVIEWS DRUG DISCOVERY
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Philippe Moreau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial
- (2016) J R Jones et al. Blood Cancer Journal
- Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations
- (2016) Christian Scharenberg et al. HAEMATOLOGICA
- HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins
- (2015) Dennis L. Buckley et al. ACS Chemical Biology
- CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL
- (2015) P. R. Hagner et al. BLOOD
- The novel mechanism of lenalidomide activity
- (2015) E. C. Fink et al. BLOOD
- Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD®immunomodulatory drug pomalidomide
- (2015) Deepika S. Das et al. BRITISH JOURNAL OF HAEMATOLOGY
- Practical Management of Lenalidomide-Related Rash
- (2015) Sara M. Tinsley et al. Clinical Lymphoma Myeloma & Leukemia
- Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma
- (2015) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance)
- (2015) John P. Leonard et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non–Germinal Center B-Cell Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study
- (2015) Grzegorz S. Nowakowski et al. JOURNAL OF CLINICAL ONCOLOGY
- Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome
- (2015) Rupa Narayan et al. LEUKEMIA & LYMPHOMA
- Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
- (2015) Jan Krönke et al. NATURE
- C2H2 zinc finger proteins greatly expand the human regulatory lexicon
- (2015) Hamed S Najafabadi et al. NATURE BIOTECHNOLOGY
- Tunable and reversible drug control of protein production via a self-excising degron
- (2015) Hokyung K Chung et al. Nature Chemical Biology
- Catalytic in vivo protein knockdown by small-molecule PROTACs
- (2015) Daniel P Bondeson et al. Nature Chemical Biology
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma
- (2015) Jia Ruan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
- (2015) A. Keith Stewart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Kaposi Sarcoma–Associated Herpesvirus-Associated Malignancies: Epidemiology, Pathogenesis, and Advances in Treatment
- (2015) Manisha Bhutani et al. SEMINARS IN ONCOLOGY
- Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma
- (2014) Shang-Yi Huang et al. ANNALS OF HEMATOLOGY
- Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment
- (2014) C. Pawlyn et al. BLOOD
- Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
- (2014) P. G. Richardson et al. BLOOD
- Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma
- (2014) Min Jung Lee et al. BRITISH JOURNAL OF HAEMATOLOGY
- Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma
- (2014) Ethan Toumishey et al. CANCER
- Role of Casein Kinase 1A1 in the Biology and Targeted Therapy of del(5q) MDS
- (2014) Rebekka K. Schneider et al. CANCER CELL
- Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways
- (2014) Balaji Balasa et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide
- (2014) Anna Jonasova et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Bone marrow immunophenotyping by flow cytometry in refractory cytopenia of childhood
- (2014) A. M. Aalbers et al. HAEMATOLOGICA
- Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia
- (2014) Marcus Järås et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
- (2014) Eric S. Fischer et al. NATURE
- Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
- (2014) Lotfi Benboubker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Autologous Transplantation and Maintenance Therapy in Multiple Myeloma
- (2014) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Erratum: Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
- (2014) D S Siegel et al. Blood Cancer Journal
- Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sezary syndrome
- (2013) C. Querfeld et al. BLOOD
- High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone
- (2013) Daniel Heintel et al. BRITISH JOURNAL OF HAEMATOLOGY
- Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity
- (2013) Anita K. Gandhi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN
- (2013) Anita K. Gandhi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC
- (2013) Shauna M. Collins et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Risk of Rash Associated With Lenalidomide in Cancer Patients: A Systematic Review of the Literature and Meta-analysis
- (2013) Beatrice Nardone et al. Clinical Lymphoma Myeloma & Leukemia
- Disruption of the Cereblon Gene Enhances Hepatic AMPK Activity and Prevents High-Fat Diet-Induced Obesity and Insulin Resistance in Mice
- (2013) K. M. Lee et al. DIABETES
- A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid®) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial
- (2013) Franck Morschhauser et al. EUROPEAN JOURNAL OF CANCER
- Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study
- (2013) Andre Goy et al. JOURNAL OF CLINICAL ONCOLOGY
- Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy
- (2013) A Thakurta et al. LEUKEMIA
- The clinical significance of cereblon expression in multiple myeloma
- (2013) Steven R. Schuster et al. LEUKEMIA RESEARCH
- Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
- (2013) J. Kronke et al. SCIENCE
- The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
- (2013) G. Lu et al. SCIENCE
- The Ubiquitin System, an Immense Realm
- (2012) Alexander Varshavsky Annual Review of Biochemistry
- The Ubiquitin Code
- (2012) David Komander et al. Annual Review of Biochemistry
- Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma
- (2012) Yibin Yang et al. CANCER CELL
- Lenalidomide enhances anti-myeloma cellular immunity
- (2012) Katarina Luptakova et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Cancer Vulnerabilities Unveiled by Genomic Loss
- (2012) Deepak Nijhawan et al. CELL
- Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
- (2012) Xavier C. Badoux et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma
- (2012) Yuan Xiao Zhu et al. LEUKEMIA & LYMPHOMA
- Greasy tags for protein removal
- (2012) Taavi K. Neklesa et al. NATURE
- Aiolos promotes TH17 differentiation by directly silencing Il2 expression
- (2012) Francisco J Quintana et al. NATURE IMMUNOLOGY
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Philip L. McCarthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease
- (2011) M. Q. Lacy et al. BLOOD
- A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605
- (2011) M. A. Sekeres et al. BLOOD
- Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma
- (2011) S. Madan et al. BLOOD
- A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
- (2011) J. A. Zonder et al. BLOOD
- Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
- (2011) Y. X. Zhu et al. BLOOD
- A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors
- (2011) George R. Simon et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Shedding light on an old mystery: Thalidomide suppresses survival pathways to induce limb defects
- (2011) Jürgen Knobloch et al. CELL CYCLE
- Phase I Study of E7820, an Oral Inhibitor of Integrin -2 Expression with Antiangiogenic Properties, in Patients with Advanced Malignancies
- (2011) M. Mita et al. CLINICAL CANCER RESEARCH
- TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression
- (2011) Martin Jädersten et al. JOURNAL OF CLINICAL ONCOLOGY
- Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis
- (2011) M. CARRIER et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- CKIα ablation highlights a critical role for p53 in invasiveness control
- (2011) Ela Elyada et al. NATURE
- Small-molecule hydrophobic tagging–induced degradation of HaloTag fusion proteins
- (2011) Taavi K Neklesa et al. Nature Chemical Biology
- Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
- (2011) Antonio Di Stasi et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia
- (2010) T. A. Fehniger et al. BLOOD
- Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
- (2010) P. G. Richardson et al. BLOOD
- Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide
- (2010) I N M Micallef et al. BONE MARROW TRANSPLANTATION
- Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab
- (2010) M. S. van der Veer et al. HAEMATOLOGICA
- Dose Escalation of Lenalidomide in Relapsed or Refractory Acute Leukemias
- (2010) William Blum et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo
- (2010) Zhengzi Qian et al. LEUKEMIA RESEARCH
- Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell–like and Foxp3+ regulatory T cells
- (2010) Roopali Gandhi et al. NATURE IMMUNOLOGY
- Identification of a Primary Target of Thalidomide Teratogenicity
- (2010) T. Ito et al. SCIENCE
- Comparative efficacy of thalidomide and prednisolone in the treatment of moderate to severe erythema nodosum leprosum: A randomized study
- (2009) Inderjeet Kaur et al. AUSTRALASIAN JOURNAL OF DERMATOLOGY
- How I treat multiple myeloma in younger patients
- (2009) A. K. Stewart et al. BLOOD
- Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma
- (2009) D. Chauhan et al. BLOOD
- Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma
- (2009) Christine Chen et al. BRITISH JOURNAL OF HAEMATOLOGY
- In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma
- (2009) E. M. Ocio et al. HAEMATOLOGICA
- An auxin-based degron system for the rapid depletion of proteins in nonplant cells
- (2009) Kohei Nishimura et al. NATURE METHODS
- Deletion ofIKZF1and Prognosis in Acute Lymphoblastic Leukemia
- (2009) Charles G. Mullighan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure
- (2008) M. Wang et al. BLOOD
- Quantification of Thyroglobulin, a Low-Abundance Serum Protein, by Immunoaffinity Peptide Enrichment and Tandem Mass Spectrometry
- (2008) A. N. Hoofnagle et al. CLINICAL CHEMISTRY
- IRF4 addiction in multiple myeloma
- (2008) Arthur L. Shaffer et al. NATURE
- BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros
- (2008) Charles G. Mullighan et al. NATURE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started